Actively Recruiting
Evaluating Safety and Effectiveness of Etentamig and ABBV-2001 with Other Drugs in Adults with Multiple Myeloma
Led by AbbVie · Updated on 2026-10-19
602
Participants Needed
36
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Multiple myeloma is a type of blood cancer that affects plasma cells typically found in the bones and bone marrow. This cancer can cause bone pain, fractures, infections, weak bones, and kidney failure. The study is designed to evaluate the safety, effectiveness, and how the body processes two investigational drugs, Etentamig and ABBV-2001, in adults with multiple myeloma, including those newly diagnosed or with relapsed or refractory disease. The study includes eight substudies with dose escalation and expansion phases. Participants in substudies 1-4 will receive increasing doses of Etentamig alone or combined with other drugs like daratumumab, lenalidomide, carfilzomib, and dexamethasone, delivered intravenously or by subcutaneous injection. Substudies 5-8 involve up to two doses of ABBV-2001 combined with oral agents such as iberdomide, mezigdomide, pomalidomide, or lenalidomide. Treatments are given according to dose levels determined during escalation phases, and the total study duration is about 130 months. Throughout the study, participants will attend regular hospital or clinic visits for medical assessments, blood tests, and side effect monitoring. Researchers will use questionnaires and other evaluations to track treatment effects and adverse events. The primary outcomes include monitoring adverse events and dose-limiting toxicities, with secondary measures including response rates, progression-free survival, duration of response, time to progression, and minimal residual disease negativity over the course of the study.
CONDITIONS
Brief Title
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Research Team
A
ABBVIE CALL CENTER
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here